|
|
|
28 Mar 2006 |
PRP Announces Initiation of a Phase I Study of a New Potential
|
|
25 Mar 2006 |
SD Pharmaceuticals Inc. Reports Positive Efficacy Data on Its Non-Immunogenic Paclitaxel Formulation
|
|
21 Mar 2006 |
Kurve Technology Signs Agreement With Schering-Plough Corporation
|
|
20 Mar 2006 |
SurModics Completes Enrollment of Phase I Clinical Trial of the I-vation(TM) Intravitreal Implant
|
|
15 Mar 2006 |
Eurand's AdvaTab Cetirizine Successfully Meets Major Development Milestone
|
|
14 Mar 2006 |
Arrowhead Research Subsidiary, Insert Therapeutics, Receives FDA Approval for IT-101 Phase I Clinical Trial; Clinical Trials for Patented Nanotechnology-Based Therapeutic Set to Begin
|
|
14 Mar 2006 |
XenoPort Initiates Phase 3 Clinical Program for XP13512 as a Treatment for Restless Legs Syndrome
|
|
10 Mar 2006 |
FDA Declares Daytrana™ NDA Resubmission To Be Complete Class I Response
|
|
09 Mar 2006 |
NovaDel Announces That Ondansetron Oral Spray Has Met The Key Regulatory Requirement Of Bioequivalence; NovaDel's partner, Hana Biosciences, Has Completed Its Clinical Program to Support a 505(b)(2) NDA submission in 2006
|
|
08 Mar 2006 |
Emisphere Announces Oral PTH License Agreement
|
|
08 Mar 2006 |
Generex Biotechnology Announces Positive Preliminary Results In A Long-Term Clinical Trial Of Generex Oral-Lyn™ In Juvenile Patients With Type-1 Diabetes Mellitus (Dm)
|
|
06 Mar 2006 |
MannKind Initiates Two U.S. Pivotal Phase 3 Studies of Inhaled Technosphere(R) Insulin
|
|
03 Mar 2006 |
Generex Biotechnology Completes Positive Pre-NDS Meeting With Health Canada for Generex Oral-lyn(TM)
|
|
02 Mar 2006 |
Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray for Treatment of Obesity and Will Advance Its Clinical Development
|
|
02 Mar 2006 |
Neupro® Receives Approvable Letter from FDA for Early Parkinson's Disease in USA
|
|
02 Mar 2006 |
Nuvo Provides Update On Long-Term Safety Trial For Pennsaid®
|
|
02 Mar 2006 |
BioDelivery Sciences Receives Non-Approvable Notification from FDA on Emezine®
|
|
01 Mar 2006 |
RxKinetix Completes Its End of Phase 2 Meeting With the FDA for RK-0202 in Oral Mucositis and is Moving Into Phase 3
|
|
28 Feb 2006 |
Positive results published for D-Pharm's DP-VPA in epilepsy.
|
|
28 Feb 2006 |
U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder
|
|
27 Feb 2006 |
ConjuChem to Initiate Phase I/II Clinical Study of PC-DAC(TM): Exendin-4 for Type 2 Diabetes
|
|
24 Feb 2006 |
Pro-Pharmaceuticals Presents Phase II/III Clinical Trials at the Central European Society for Anti-Cancer Drug Research Conference
|
|
23 Feb 2006 |
Javelin presents intranasal morphine safety and efficacy data at the American Academy of Pain Medicine
|
|
22 Feb 2006 |
SkinMedica® Reports Positive Results From Desonate™ Phase III Trials
|
|
21 Feb 2006 |
Inspire Announces Development and License Agreement with Boehringer Ingelheim International for Intranasal Epinastine in the United States and Canada
|
|
17 Feb 2006 |
ORADUR™ Technology Milestone: Remoxy™ (ORADUR-based oxycodone) Receives Special Protocol Assessment and Commences Pivotal Phase III
|
|
17 Feb 2006 |
Alkermes Announces Submission of Complete Response to FDA for VIVITROL™ New Drug Application
|
|
17 Feb 2006 |
BioSante Pharmaceuticals Announces Bio-E-Gel™ NDA Submission
|
|
17 Feb 2006 |
King Pharmaceuticals and Arrow International limited and affiliates collaborate on new formulations of Altace®
|
|
16 Feb 2006 |
SCOLR Pharma Reports Positive Ondansetron Clinical Results, New Drug Development Targets, and Revised Development Priorities
|
|
16 Feb 2006 |
Survival Benefit Linked to Estrogen in Women Treated With XYOTAX(TM)
|
|
15 Feb 2006 |
Biolex Therapeutics Presents Results Highlighting Benefits of Locteron(TM) at 'Breakthroughs in Hepatitis' Session
|
|
15 Feb 2006 |
Emisphere Achieves Second Milestone in Roche Collaboration
|
|
15 Feb 2006 |
Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
|
|
10 Feb 2006 |
Penwest Reports Positive Results For Phase IIa Trial of PW4142
|
|
10 Feb 2006 |
NeoPharm Announces LEP-ETU Project Update
|
|
10 Feb 2006 |
NeurogesX Announces Presentation of Positive Phase 3 Results in Painful HIV-Associated Neuropathy at CROI
|
|
09 Feb 2006 |
Insert Therapeutics Files Investigational New Drug Application for Lead Anti-Cancer Compound IT-101
|
|
08 Feb 2006 |
XYOTAX(TM) has FDA Fast Track Designation for Women With Advanced Lung Cancer Who are Performance Status 2
|
|
07 Feb 2006 |
Procyon Presents Preclinical Results with its Novel Tumor Vasculature Targeting Drug, TVT-DOX, at the 2006 Miami Nature Biotechnology Symposium on Angiogenesis in Cancer
|
|
07 Feb 2006 |
TheraQuest's Abuse Deterrent Tramadol ER IND for Neuropathic Pain Accepted by FDA
|
|
07 Feb 2006 |
BioSante Pharmaceuticals Announces Subcontract with the University of Nebraska-Lincoln Using its Proprietary CaP Drug Delivery System
|
|
03 Feb 2006 |
Shire announces European filings of SPD476 (mesalazine) for treatment of ulcerative colitis
|
|
02 Feb 2006 |
Altea Therapeutics and Teikoku Seiyaku Co. Ltd. Enter into an Agreement for the Development, Manufacture, and Commercialization in Japan of a New Transdermal Therapy for Parkinson's Disease
|
|
01 Feb 2006 |
Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
|
|
01 Feb 2006 |
Abeille Initiates Phase I Clinical Trial of AB-1001 for Prevention of Emesis Associated With Chemo- and Radiation Therapy
|
|
01 Feb 2006 |
LifeCycle Pharma Heads into Pivotal Trials with its Immunosuppression Product
|
|
01 Feb 2006 |
FDA Accepts IND for Elite Pharmaceuticals Once-Daily Oxycodone Product
|
|
31 Jan 2006 |
European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System)
|
|
28 Jan 2006 |
Pfizer Receives FDA Approval for Exubera, the First Inhalable Form of Insulin for Controlling Type 1 and Type 2 Diabetes in Adults
|
| |
|
Results 351 - 400 of 411 |
